1
|
GABA B receptors in the hypothalamic paraventricular nucleus mediate β-adrenoceptor-induced elevations of plasma noradrenaline in rats. Eur J Pharmacol 2019; 848:88-95. [PMID: 30685430 DOI: 10.1016/j.ejphar.2019.01.029] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2018] [Revised: 01/15/2019] [Accepted: 01/18/2019] [Indexed: 11/21/2022]
Abstract
In the brain, various neurotransmitters such as noradrenaline and GABA regulate peripheral sympathetic functions. Previously, it has been reported that both β-adrenoceptor activation and GABAB receptor activation in the brain are involved in the elevation of plasma noradrenaline levels. However, it is unknown whether these pathways interact with each other. In the present study, we examined the relationship between the central actions of β-adrenoceptor activation and GABAB receptor activation with regard to plasma noradrenaline responses using urethane-anesthetized rats. Intracerebroventricular pretreatment with the GABAA receptor antagonist bicuculline did not affect the β-adrenoceptor agonist isoproterenol-induced elevation of plasma noradrenaline levels. In contrast, pretreatment with the GABAB receptor antagonist CGP 35348 suppressed the isoproterenol-induced elevation of noradrenaline levels. Intracerebroventricular pretreatment with the β-adrenoceptor antagonist propranolol did not alter the GABAB receptor agonist baclofen-induced elevation of plasma noradrenaline levels. We next examined the central effects of β-adrenoceptor activation on GABA release in the paraventricular hypothalamic nucleus (PVN), the major integrative center for sympathetic regulation in the brain. Intracerebroventricular administration of isoproterenol increased GABA content in PVN dialysates. In addition, baclofen microinjected unilaterally into the PVN resulted in elevated plasma levels of noradrenaline, but not adrenaline. Finally, unilateral blockade of GABAB receptors in the PVN suppressed the isoproterenol-induced elevation of plasma noradrenaline level. Our results suggest that activation of β-adrenoceptors in the brain, likely in the PVN, induces GABA release in the PVN, which in turn activates GABAB receptors in the PVN, leading to elevated plasma noradrenaline.
Collapse
|
2
|
Okada S, Yamaguchi N. Possible role of adrenoceptors in the hypothalamic paraventricular nucleus in corticotropin-releasing factor-induced sympatho-adrenomedullary outflow in rats. Auton Neurosci 2017; 203:74-80. [PMID: 28202248 DOI: 10.1016/j.autneu.2017.01.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 12/30/2016] [Accepted: 01/20/2017] [Indexed: 02/07/2023]
Abstract
AIMS A functional interaction between the corticotropin-releasing factor (CRF) system and noradrenergic neurons in the brain has been suggested. In the present study, we investigated the interrelationship between the central CRF-induced elevation of plasma catecholamines and adrenoceptor activation in the paraventricular nucleus of the hypothalamus (PVN) using urethane-anesthetized rats. MAIN METHODS In rats under urethane anesthesia, a femoral venous line was inserted for infusion of saline, and a femoral arterial line was inserted for collecting blood samples. Next, animals were placed in a stereotaxic apparatus for the application of test agents. Catecholamines in the plasma were extracted by alumina absorption and were assayed with high-performance liquid chromatography with electrochemical detection. Quantification of noradrenaline in rat PVN microdialysates was performed with high-performance liquid chromatography with electrochemical detection. KEY FINDINGS We showed that centrally administered CRF elevated noradrenaline release in the PVN. Furthermore, we demonstrated that microinjection of phenylephrine into the PVN induced elevation of plasma levels of adrenaline, but not of noradrenaline, whereas microinjection of isoproterenol into the PVN induced elevation of plasma levels of noradrenaline, but not of adrenaline. Bilateral blockade of adrenoceptors in the PVN revealed that phentolamine significantly suppressed the CRF-induced elevation of plasma adrenaline level, while propranolol significantly CRF-induced elevation of plasma noradrenaline level. SIGNIFICANCE Our results suggest that centrally administered CRF-induced elevation of plasma levels of adrenaline and noradrenaline can be mediated via activation of α-adrenoceptors and β-adrenoceptors, respectively, in the rat PVN.
Collapse
Affiliation(s)
- Shoshiro Okada
- Department of Pharmacology, Graduate School of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan.
| | - Naoko Yamaguchi
- Department of Pharmacology, Graduate School of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan
| |
Collapse
|
3
|
Grzęda E, Schlicker E, Toczek M, Zalewska I, Baranowska-Kuczko M, Malinowska B. CB 1 receptor activation in the rat paraventricular nucleus induces bi-directional cardiovascular effects via modification of glutamatergic and GABAergic neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 2016; 390:25-35. [PMID: 27659492 PMCID: PMC5203819 DOI: 10.1007/s00210-016-1302-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 09/05/2016] [Indexed: 01/21/2023]
Abstract
We have shown previously that the cannabinoid receptor agonist CP55940 microinjected into the paraventricular nucleus of the hypothalamus (PVN) of urethane-anaesthetized rats induces depressor and pressor cardiovascular effects in the absence and presence of the CB1 antagonist AM251, respectively. The aim of our study was to examine whether the hypotension and/or hypertension induced by CP55940 given into the PVN results from its influence on glutamatergic and GABAergic neurotransmission. CP55940 was microinjected into the PVN of urethane-anaesthetized rats twice (S1 and S2, 20 min apart). Antagonists of the following receptors, NMDA (MK801), β2-adrenergic (ICI118551), thromboxane A2–TP (SQ29548), angiotensin II–AT1 (losartan) or GABAA (bicuculline), or the NO synthase inhibitor L-NAME were administered intravenously 5 min before S2 alone or together with AM251. The CP55940-induced hypotension was reversed into a pressor response by AM251, bicuculline and L-NAME, but not by the other antagonists. The CP55940-induced pressor effect examined in the presence of AM251 was completely reversed by losartan, reduced by about 50–60 % by MK801, ICI118551 and SQ29548, prevented by bilateral adrenalectomy but not modified by bicuculline and L-NAME. Parallel, but smaller, changes in heart rate accompanied the changes in blood pressure. The bi-directional CB1 receptor-mediated cardiovascular effects of cannabinoids microinjected into the PVN of anaesthetized rats depend on stimulatory glutamatergic and inhibitory GABAergic inputs to the sympathetic tone; the glutamatergic input is related to AT1, TP and β2-adrenergic receptors and catecholamine release from the adrenal medulla whereas the GABAergic input is reinforced by NO.
Collapse
MESH Headings
- Adrenalectomy
- Animals
- Blood Pressure/drug effects
- Cannabinoid Receptor Agonists/administration & dosage
- Cannabinoid Receptor Agonists/toxicity
- Cyclohexanols/administration & dosage
- Cyclohexanols/toxicity
- Glutamic Acid/metabolism
- Heart Rate/drug effects
- Hypertension/chemically induced
- Hypertension/metabolism
- Hypertension/physiopathology
- Hypotension/chemically induced
- Hypotension/metabolism
- Hypotension/physiopathology
- Male
- Microinjections
- Neural Inhibition/drug effects
- Neural Pathways/drug effects
- Neural Pathways/metabolism
- Neural Pathways/physiopathology
- Nitric Oxide/metabolism
- Paraventricular Hypothalamic Nucleus/drug effects
- Paraventricular Hypothalamic Nucleus/metabolism
- Paraventricular Hypothalamic Nucleus/physiopathology
- Rats, Wistar
- Receptor, Angiotensin, Type 1/metabolism
- Receptor, Cannabinoid, CB1/agonists
- Receptor, Cannabinoid, CB1/metabolism
- Receptors, Adrenergic, beta-2/metabolism
- Receptors, Thromboxane A2, Prostaglandin H2/metabolism
- Sympathetic Nervous System/drug effects
- Sympathetic Nervous System/metabolism
- Sympathetic Nervous System/physiopathology
- Synaptic Transmission/drug effects
- gamma-Aminobutyric Acid/metabolism
Collapse
Affiliation(s)
- Emilia Grzęda
- Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, Białystok, Poland
| | - Eberhard Schlicker
- Department of Pharmacology and Toxicology, University of Bonn, Bonn, Germany
| | - Marek Toczek
- Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, Białystok, Poland
| | - Iwona Zalewska
- Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, Białystok, Poland
| | - Marta Baranowska-Kuczko
- Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, Białystok, Poland
| | - Barbara Malinowska
- Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, Białystok, Poland.
| |
Collapse
|
4
|
NMDA Receptor Plasticity in the Hypothalamic Paraventricular Nucleus Contributes to the Elevated Blood Pressure Produced by Angiotensin II. J Neurosci 2015; 35:9558-67. [PMID: 26134639 DOI: 10.1523/jneurosci.2301-14.2015] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Hypertension induced by angiotensin II (Ang II) is associated with glutamate-dependent dysregulation of the hypothalamic paraventricular nucleus (PVN). Many forms of glutamate-dependent plasticity are mediated by NMDA receptor GluN1 subunit expression and the distribution of functional receptor to the plasma membrane of dendrites. Here, we use a combined ultrastructural and functional analysis to examine the relationship between PVN NMDA receptors and the blood pressure increase induced by chronic infusion of a low dose of Ang II. We report that the increase in blood pressure produced by a 2 week administration of a subpressor dose of Ang II results in an elevation in plasma membrane GluN1 in dendrites of PVN neurons in adult male mice. The functional implications of these observations are further demonstrated by the finding that GluN1 deletion in PVN neurons attenuated the Ang II-induced increases in blood pressure. These results indicate that NMDA receptor plasticity in PVN neurons significantly contributes to the elevated blood pressure mediated by Ang II.
Collapse
|
5
|
Kondo F, Tachi M, Gosho M, Fukayama M, Yoshikawa K, Okada S. Changes in hypothalamic neurotransmitter and prostanoid levels in response to NMDA, CRF, and GLP-1 stimulation. Anal Bioanal Chem 2015; 407:5261-72. [PMID: 25633219 DOI: 10.1007/s00216-015-8496-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2014] [Revised: 01/13/2015] [Accepted: 01/14/2015] [Indexed: 11/25/2022]
Abstract
Determination of neuroactive substances, such as neurotransmitters and prostanoids, in the extracellular space of the living brain is a very important technique in neuroscience. The hypothalamic paraventricular nucleus (PVN) is one of the most important autonomic control centers in the brain. Recently, we demonstrated that thromboxane (Tx) A2 in the PVN may play an important role in adrenomedullary outflow evoked by N-methyl-D-aspartate (NMDA), corticotrophin-releasing factor (CRF), and glucagon-like peptide-1 (GLP-1) stimulation using microdialysis sampling and liquid chromatography-ion trap tandem mass spectrometry (LC-ITMS(n)). In the present study, we investigated whether centrally administered NMDA, CRF, and GLP-1 can release five neurotransmitters, acetylcholine (ACh), histamine, glutamate (Glu), γ-aminobutyric acid (GABA), and serotonin (5-HT), along with six prostanoids, TxB2, prostaglandin (PG) E2, PGD2, 15-deoxy-∆(12,14) (15d)-PGJ2, 6-keto-PGF1α, and PGF2α in rat PVN microdialysates after optimization of LC-ITMS(n) conditions . All stimulations increased the levels of 5-HT, TxB2, PGE2, and PGF2α (except for 5-HT stimulated with GLP-1). Only NMDA increased the levels of ACh, Glu, and GABA. Treatment with dizocilpine maleate (MK-801), a noncompetitive NMDA receptor antagonist, attenuated the NMDA-induced increase in the levels of neuroactive substances except for Glu. This is the first study to use LC-ITMS(n) to analyze neurotransmitters and prostanoids in the same microdialysates from rat PVN.
Collapse
Affiliation(s)
- Fumio Kondo
- Department of Pharmacology, Aichi Medical University School of Medicine, Nagakute, Aichi, 480-1195, Japan,
| | | | | | | | | | | |
Collapse
|
6
|
Ando K, Kondo F, Yamaguchi N, Tachi M, Fukayama M, Yoshikawa K, Gosho M, Fujiwara Y, Okada S. Centrally administered isoproterenol induces sympathetic outflow via brain prostaglandin E2-mediated mechanisms in rats. Auton Neurosci 2014; 189:1-7. [PMID: 25549851 DOI: 10.1016/j.autneu.2014.12.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Revised: 12/11/2014] [Accepted: 12/13/2014] [Indexed: 01/27/2023]
Abstract
Brain β-adrenoceptor stimulation can induce elevations of plasma levels of noradrenaline. However, there have been no detailed studies related to signaling pathways downstream of β-adrenoceptors responsible for central sympathetic outflow. In the present study, we pharmacologically examined the possibility that centrally administered isoproterenol can induce elevations of plasma noradrenaline levels in a brain prostaglandin-dependent manner. In addition, we also examined whether or not intracerebroventricular administration of isoproterenol could release endogenously synthesized prostaglandin (PG) E2 in the hypothalamic paraventricular nucleus (PVN) by using the brain microdialysis technique combined with liquid chromatography-ion trap tandem mass spectrometry (LC-ITMS(n)). Under urethane anesthesia, a femoral venous line was inserted for infusion of saline and a femoral arterial line was inserted for collecting blood samples. Next, animals were placed in a stereotaxic apparatus for application of test agents. Catecholamines in the plasma were extracted by alumina absorption and were assayed by high-performance liquid chromatography with electrochemical detection. Quantification of PGE2 in rat PVN microdialysates was performed by the LC-ITMS(n) method. We demonstrated that centrally administered isoproterenol-induced elevations of plasma noradrenaline could be mediated via activation of β-adrenoceptors and the downstream phospholipase A2-cyclooxygenase pathway. Furthermore, PGE2 in the PVN and the PGE2 receptor EP3 subtype appear to play an important role in the process. Our results suggest that central isoproterenol-induced sympathetic outflow is mediated via brain PGE2 in a PGE2 receptor EP3 subtype-dependent manner.
Collapse
Affiliation(s)
- Kazuo Ando
- Department of Anesthesiology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Fumio Kondo
- Department of Pharmacology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Naoko Yamaguchi
- Department of Pharmacology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Masahiko Tachi
- Department of Pharmacology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Minoru Fukayama
- Advanced Medical Research Center, Aichi Medical University, Nagakute, Aichi, Japan
| | - Kazuhiro Yoshikawa
- Advanced Medical Research Center, Aichi Medical University, Nagakute, Aichi, Japan
| | - Masahiko Gosho
- Advanced Medical Research Center, Aichi Medical University, Nagakute, Aichi, Japan
| | - Yoshihiro Fujiwara
- Department of Anesthesiology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
| | - Shoshiro Okada
- Department of Pharmacology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
| |
Collapse
|
7
|
Mass spectrometric determination of prostanoids in rat hypothalamic paraventricular nucleus microdialysates. Auton Neurosci 2014; 181:49-54. [DOI: 10.1016/j.autneu.2013.12.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2013] [Revised: 12/10/2013] [Accepted: 12/30/2013] [Indexed: 11/21/2022]
|
8
|
Ramadan E, Basselin M, Rao JS, Chang L, Chen M, Ma K, Rapoport SI. Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder. Int J Neuropsychopharmacol 2012; 15:931-43. [PMID: 21733229 PMCID: PMC3204186 DOI: 10.1017/s1461145711001003] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
An up-regulated brain arachidonic acid (AA) cascade and a hyperglutamatergic state characterize bipolar disorder (BD). Lamotrigine (LTG), a mood stabilizer approved for treating BD, is reported to interfere with glutamatergic neurotransmission involving N-methyl-d-aspartate receptors (NMDARs). NMDARs allow extracellular calcium into the cell, thereby stimulating calcium-dependent cytosolic phospholipase A2 (cPLA2) to release AA from membrane phospholipid. We hypothesized that LTG, like other approved mood stabilizers, would reduce NMDAR-mediated AA signalling in rat brain. An acute subconvulsant dose of NMDA (25 mg/kg) or saline was administered intraperitoneally to unanaesthetized rats that had been treated p.o. daily for 42 d with vehicle or a therapeutically relevant dose of LTG (10 mg/kg.d). Regional brain AA incorporation coefficients k* and rates J in, and AA signals, were measured using quantitative autoradiography after intravenous [1-14C]AA infusion, as were other AA cascade markers. In chronic vehicle-treated rats, acute NMDA compared to saline increased k* and J in in widespread regions of the brain, as well as prostaglandin (PG)E2 and thromboxane B2 concentrations. Chronic LTG treatment compared to vehicle reduced brain cyclooxygenase (COX) activity, PGE2 concentration, and DNA-binding activity of the COX-2 transcription factor, NF-κB. Pretreatment with chronic LTG blocked the acute NMDA effects on AA cascade markers. In summary, chronic LTG like other mood stabilizers blocks NMDA-mediated signalling involving the AA metabolic cascade. Since markers of the AA cascade and of NMDAR signalling are up-regulated in the post-mortem BD brain, mood stabilizers generally may be effective in BD by dampening NMDAR signalling and the AA cascade.
Collapse
Affiliation(s)
- Epolia Ramadan
- Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.
| | | | | | | | | | | | | |
Collapse
|
9
|
α1-Adrenoceptor activation is involved in the central N-methyl-d-aspartate-induced adrenomedullary outflow in rats. Eur J Pharmacol 2010; 640:55-62. [DOI: 10.1016/j.ejphar.2010.04.038] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2009] [Revised: 04/09/2010] [Accepted: 04/25/2010] [Indexed: 02/02/2023]
|
10
|
Involvement of central β2-adrenergic, NMDA and thromboxane A2 receptors in the pressor effect of anandamide in rats. Naunyn Schmiedebergs Arch Pharmacol 2010; 381:349-60. [DOI: 10.1007/s00210-010-0497-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2010] [Accepted: 02/06/2010] [Indexed: 10/19/2022]
|
11
|
Shimizu T, Yokotani K. Brain cyclooxygenase and prostanoid TP receptors are involved in centrally administered epibatidine-induced secretion of noradrenaline and adrenaline from the adrenal medulla in rats. Eur J Pharmacol 2009; 606:77-83. [DOI: 10.1016/j.ejphar.2009.01.032] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2008] [Revised: 01/06/2009] [Accepted: 01/19/2009] [Indexed: 02/07/2023]
|
12
|
Basselin M, Chang L, Chen M, Bell JM, Rapoport SI. Chronic administration of valproic acid reduces brain NMDA signaling via arachidonic acid in unanesthetized rats. Neurochem Res 2008; 33:2229-40. [PMID: 18461450 PMCID: PMC2564799 DOI: 10.1007/s11064-008-9700-2] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2008] [Accepted: 04/03/2008] [Indexed: 01/12/2023]
Abstract
Evidence that brain glutamatergic activity is pathologically elevated in bipolar disorder suggests that mood stabilizers are therapeutic in the disease in part by downregulating glutamatergic activity. Such activity can involve the second messenger, arachidonic acid (AA, 20:4n - 6). We tested this hypothesis with regard to valproic acid (VPA), when stimulating glutamatergic N-methyl-D: -aspartate (NMDA) receptors in rat brain and measuring AA and related responses. An acute subconvulsant dose of NMDA (25 mg/kg i.p.) or saline was administered to unanesthetized rats that had been treated i.p. daily with VPA (200 mg/kg) or vehicle for 30 days. Quantitative autoradiography following intravenous [1-(14)C]AA infusion was used to image regional brain AA incorporation coefficients k*, markers of AA signaling. In chronic vehicle-pretreated rats, NMDA compared with saline significantly increased k* in 41 of 82 examined brain regions, many of which have high NMDA receptor densities, and also increased brain concentrations of the AA metabolites, prostaglandin E(2) (PGE(2)) and thromboxane B(2) (TXB(2)). VPA pretreatment reduced baseline concentrations of PGE(2) and TXB(2), and blocked the NMDA induced increases in k* and in eicosanoid concentrations. These results, taken with evidence that carbamazepine and lithium also block k* responses to NMDA in rat brain, suggest that mood stabilizers act in bipolar disorder in part by downregulating glutamatergic signaling involving AA.
Collapse
Affiliation(s)
- Mireille Basselin
- Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bldg 9, Room 1S126, MSC 0947, 9 Memorial Drive, Bethesda, MD, 20892, USA.
| | | | | | | | | |
Collapse
|
13
|
Okada S, Yamaguchi-Shima N, Shimizu T, Arai J, Lianyi L, Wakiguchi H, Yokotani K. Role of brain nicotinic acetylcholine receptor in centrally administered corticotropin-releasing factor-induced elevation of plasma corticosterone in rats. Eur J Pharmacol 2008; 587:322-9. [PMID: 18423439 DOI: 10.1016/j.ejphar.2008.03.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2007] [Revised: 02/22/2008] [Accepted: 03/03/2008] [Indexed: 11/30/2022]
Abstract
The present study was undertaken to clarify the central mechanisms involved in the intracerebroventricularly administered corticotropin-releasing factor-induced elevation of plasma corticosterone in urethane- and alpha-chloralose-anesthetized rats using microdialysis and immunohistochemical techniques. When corticotropin-releasing factor was given at 0.5, 1.5, and 3.0 nmol/animal intracerebroventricularly, it dose-dependently increased noradrenaline release but not adrenaline release in the hypothalamic paraventricular nucleus. The 1.5 nmol/animal dose of corticotropin-releasing factor-induced noradrenaline release was attenuated by CP-154,526 (butyl-ethyl-{2,5-dimethyl-7-(2,4,6 trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amine), a selective corticotropin-releasing factor receptor 1 antagonist, at 1.3 micromol/animal, intracerebroventricularly, and was also abolished by phentolamine at 0.66 micromol/animal, intracerebroventricularly. In addition, the corticotropin-releasing factor-induced elevation of noradrenaline release in the hypothalamic paraventricular nucleus and plasma corticosterone were abolished by hexamethonium, a non-selective nicotinic acetylcholine receptor antagonist, at 1.8 micromol/animal, intracerebroventricularly, and alpha-conotoxin MII, a potent alpha(3)beta(2) nicotinic acetylcholine receptor antagonist, at 30 nmol/animal, i.c.v. Corticotropin-releasing factor at 1.5 nmol/animal, i.c.v. evoked a significant expression of Fos, an immediate-early transcription factor in neurons, on the dopamine-beta-hydroxylase-containing neurons and alpha(3) nicotinic acetylcholine receptor subunit-expressing neurons in the locus coeruleus, but not in the medullary A(1) and A(2) regions containing noradrenergic neurons. These results suggest that centrally administered corticotrophin-releasing factor elevates plasma corticosterone by the corticotropin-releasing factor 1 receptor and alpha(3) subunit-containing nicotinic acetylcholine receptor (probably alpha(3)beta(2) nicotinic acetylcholine receptor) mediated activation of the locus coeruleus noradrenergic neurons projecting to the paraventricular nucleus in rats.
Collapse
Affiliation(s)
- Shoshiro Okada
- Department of Pharmacology, Graduate School of Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan.
| | | | | | | | | | | | | |
Collapse
|
14
|
Okada S, Yamaguchi-Shima N, Shimizu T, Arai J, Yorimitsu M, Yokotani K. Centrally administered N-methyl-d-aspartate evokes the adrenal secretion of noradrenaline and adrenaline by brain thromboxane A2-mediated mechanisms in rats. Eur J Pharmacol 2008; 586:145-50. [PMID: 18374330 DOI: 10.1016/j.ejphar.2008.02.069] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2007] [Revised: 02/07/2008] [Accepted: 02/25/2008] [Indexed: 11/16/2022]
Abstract
Plasma adrenaline mainly originated from adrenaline-containing cells in the adrenal medulla, while plasma noradrenaline reflects the release from sympathetic nerves in addition to the secretion from noradrenaline-containing cells in the adrenal medulla. The present study was undertaken to characterize the source of plasma catecholamines induced by centrally administered N-methyl-d-aspartate with regard to the brain prostanoid, using urethane-anesthetized rats. Intracerebroventricularly (i.c.v.) administered N-methyl-d-aspartate (1.0, 5.0, 10.0 nmol/animal) dose-dependently elevated plasma levels of noradrenaline and adrenaline. The N-methyl-d-aspartate (5.0 nmol/animal, i.c.v.)-induced elevation of both catecholamines was reduced by dizocilpine maleate (5 nmol/animal, i.c.v.), a non-competitive N-methyl-d-aspartate receptor antagonist. Indomethacin (0.6 and 1.2 micromol/animal, i.c.v.), an inhibitor of cyclooxygenase, dose-dependently reduced the N-methyl-d-aspartate (5.0 nmol/animal, i.c.v.)-induced elevation of both catecholamines. The N-methyl-d-aspartate-induced response was dose-dependently attenuated by furegrelate (0.9 and 1.8 micromol/animal, i.c.v.), an inhibitor of thromboxane A2 synthase. Furthermore, the acute bilateral adrenalectomy abolished the N-methyl-d-aspartate-induced responses, indicating that the source of increase in plasma noradrenaline evoked by N-methyl-d-aspartate is due to secretion from the adrenal gland and not due to release from sympathetic nerve terminals. These results suggest that centrally administered N-methyl-d-aspartate induces the secretion of noradrenaline and adrenaline from adrenal medulla by the brain thromboxane A2-mediated mechanisms in rats.
Collapse
Affiliation(s)
- Shoshiro Okada
- Department of Pharmacology: Graduate School of Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan.
| | | | | | | | | | | |
Collapse
|
15
|
Basselin M, Villacreses NE, Chen M, Bell JM, Rapoport SI. Chronic carbamazepine administration reduces N-methyl-D-aspartate receptor-initiated signaling via arachidonic acid in rat brain. Biol Psychiatry 2007; 62:934-43. [PMID: 17628508 PMCID: PMC2131715 DOI: 10.1016/j.biopsych.2007.04.021] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2006] [Revised: 04/11/2007] [Accepted: 04/11/2007] [Indexed: 01/16/2023]
Abstract
BACKGROUND Lithium and carbamazepine (CBZ) are used to treat mania in bipolar disorder. When given chronically to rats, both agents reduce arachidonic acid (AA) turnover in brain phospholipids and downstream AA metabolism. Lithium in rats also attenuates brain N-methyl-D-aspartic acid receptor (NMDAR) signaling via AA. We hypothesized that, like chronic lithium, chronic CBZ administration to rats would reduce NMDAR-mediated signaling via AA. METHODS We used our fatty acid method with quantitative autoradiography to image the regional brain incorporation coefficient k* of AA, a marker of AA signaling, in unanesthetized rats that had been given 25 mg/kg/day I.P. CBZ or vehicle for 30 days, then injected with NMDA (25 mg/kg I.P.) or saline. We also measured brain concentrations of two AA metabolites, prostaglandin E(2) (PGE(2)) and thromboxane B(2) (TXB(2)). RESULTS In chronic vehicle-treated rats, NMDA compared with saline increased k* significantly in 69 of 82 brain regions examined, but did not change k* significantly in any region in CBZ-treated rats. In vehicle- but not CBZ-treated rats, NMDA also increased brain concentrations of PGE(2) and TXB(2). CONCLUSIONS Chronic CBZ administration to rats blocks increments in the AA signal k*, and in PGE(2) and TXB(2) concentrations that are produced by NMDA in vehicle-treated rats. The clinical action of antimanic drugs might involve inhibition of brain NMDAR-mediated signaling involving AA and its metabolites.
Collapse
Affiliation(s)
- Mireille Basselin
- Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA.
| | | | | | | | | |
Collapse
|
16
|
Yamaguchi-Shima N, Okada S, Shimizu T, Usui D, Nakamura K, Lu L, Yokotani K. Adrenal adrenaline- and noradrenaline-containing cells and celiac sympathetic ganglia are differentially controlled by centrally administered corticotropin-releasing factor and arginine-vasopressin in rats. Eur J Pharmacol 2007; 564:94-102. [PMID: 17350615 DOI: 10.1016/j.ejphar.2007.02.021] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2006] [Revised: 02/01/2007] [Accepted: 02/01/2007] [Indexed: 11/16/2022]
Abstract
The adrenal glands and sympathetic celiac ganglia are innervated mainly by the greater splanchnic nerves, which contain preganglionic sympathetic nerves that originated from the thoracic spinal cord. The adrenal medulla has two separate populations of chromaffin cells, adrenaline-containing cells (A-cells) and noradrenaline-containing cells (NA-cells), which have been shown to be differentially innervated by separate groups of the preganglionic sympathetic neurons. The present study was designed to characterize the centrally activating mechanisms of the adrenal A-cells, NA-cells and celiac sympathetic ganglia with expression of cFos (a marker for neural excitation), in regard to the brain prostanoids, in anesthetized rats. Intracerebroventricularly (i.c.v.) administered corticotropin-releasing factor (CRF) induced cFos expression in the adrenal A-cells, but not NA-cells, and celiac ganglia. On the other hand, i.c.v. administered arginine-vasopressin (AVP) resulted in cFos induction in both A-cells and NA-cells in the adrenal medulla, but not in the celiac ganglia. Intracerebroventricular pretreatment with indomethacin (an inhibitor of cyclooxygenase) abolished the CRF- and AVP-induced cFos expression in all regions described above. On the other hand, intracerebroventricular pretreatment with furegrelate (an inhibitor of thromboxane A2 synthase) abolished the CRF-induced cFos expression in the adrenal A-cells, but not in the celiac ganglia, and also abolished the AVP-induced cFos expression in both A-cells and NA-cells in the adrenal medulla. These results suggest that centrally administered CRF activates adrenal A-cells and celiac sympathetic ganglia by brain thromboxane A2-mediated and other prostanoid than thromboxane A2 (probably prostaglandin E2)-mediated mechanisms, respectively. On the other hand, centrally administered AVP activates adrenal A-cells and NA-cells by brain thromboxane A2-mediated mechanisms in rats.
Collapse
Affiliation(s)
- Naoko Yamaguchi-Shima
- Department of Pharmacology, Graduate School of Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan.
| | | | | | | | | | | | | |
Collapse
|
17
|
Yalcin M, Cavun S, Yilmaz MS, Cengiz F, Savci V. Involvement of brain thromboxane A in hypotension induced by haemorrhage in rats. Clin Exp Pharmacol Physiol 2006; 32:960-7. [PMID: 16405453 DOI: 10.1111/j.1440-1681.2005.04291.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
1. In the present study, we aimed to determine the involvement of brain thromboxane A2 (TXA2) in blood pressure decreases evoked by acute and/or graded haemorrhage in rats. 2. Sprague-Dawley rats were used throughout the study. Acute haemorrhage was achieved by withdrawing a total volume of 2.1 and 2.5 mL blood/100 g bodyweight over a period of 10 min. A microdialysis study was performed in a hypothalamic area to measure extracellular TXA2 levels. Graded haemorrhage was conducted successively by withdrawing carotid arterial blood (0.55 mL/100 g bodyweight) over a 10 s period four times (S1-S4) at 5 min intervals. Furegrelate (125, 250 and 500 microg), a TXA2 synthase inhibitor, was injected intracerebroventricularly (i.c.v.) 60 min before acute or graded haemorrhage was initiated. U-46619 (0.5, 1 and 2 microg, i.c.v.), a synthetic TXA2 analogue, was administered 5 min before acute haemorrhage (2.1 mL/100 g bodyweight). 3. Acute haemorrhage produced a severe and long-lasting decrease in blood pressure and had a tendency to increase heart rate. Both haemorrhage protocols (2.1 or 2.5 mL/100 g) generated similar approximate twofold increases in extracellular hypothalamic TXA2 levels. Intracerebroventricular furegrelate (250 microg) pretreatment completely blocked the TXA2 increases induced by acute haemorrhage. Furegrelate administration (100, 250 and 500 microg, i.c.v.) attenuated the fall in arterial pressure evoked by acute haemorrhage and caused significant increases in heart rate at all doses injected. 4. Graded haemorrhage progressively lowered arterial pressure and increased plasma vasopressin and adrenaline levels in the last period. Furegrelate-injected rats were greatly resistant to the hypotensive effect of haemorrhage for all degrees of blood removed. Plasma adrenaline and vasopressin levels were significantly elevated in furegrelate-pretreated rats compared with the saline-treated group during S2-S3 and S4, respectively. U-46619 administration caused small but statistically significant decreases in arterial pressure induced by haemorrhage. 4. The results show that acute hypotensive haemorrhage increases extracellular hypothalamic TXA2 levels. The increase in brain endogenous TXA2 levels involves a decrease in blood pressure evoked by haemorrhage because the blockade of TXA2 synthesis by furegrelate pretreatment attenuated the haemorrhagic hypotension. Increases in plasma adrenaline and vasopressin levels may mediate this effect.
Collapse
Affiliation(s)
- Murat Yalcin
- Department of Physiology, Veterinary Faculty, Uludag University, Bursa, Turkiye
| | | | | | | | | |
Collapse
|
18
|
Yokotani K, Okada S, Nakamura K, Yamaguchi-Shima N, Shimizu T, Arai J, Wakiguchi H, Yokotani K. Brain prostanoid TP receptor-mediated adrenal noradrenaline secretion and EP3 receptor-mediated sympathetic noradrenaline release in rats. Eur J Pharmacol 2005; 512:29-35. [PMID: 15814087 DOI: 10.1016/j.ejphar.2005.02.027] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2004] [Accepted: 02/18/2005] [Indexed: 11/27/2022]
Abstract
Sympathetic nerves release noradrenaline, whereas adrenal medullary chromaffin cells secrete noradrenaline and adrenaline. Therefore, plasma noradrenaline reflects the secretion from adrenal medulla in addition to the release from sympathetic nerves, however the exact mechanisms of adrenal noradrenaline secretion remain to be elucidated. The present study was designated to characterize the source of plasma noradrenaline induced by intracerebroventricularly (i.c.v.) administered bombesin and prostaglandin E2 in urethane-anesthetized rats. Bombesin (1.0 nmol/animal, i.c.v.) elevated plasma noradrenaline and adrenaline, while prostaglandin E2 (0.3 nmol/animal, i.c.v.) elevated only plasma noradrenaline. The bombesin-induced elevations of both catecholamines were attenuated by pretreatments with furegrelate (an inhibitor of thromboxane A2 synthase) [250 and 500 microg (0.9 and 1.8 micromol)/animal, i.c.v.)] and [(+)-S-145] [(+)-(1R,2R,3S,4S)-(5Z)-7-(3-[4-3H]-phenylsulphonyl-aminobicyclo[2.2.1]hept-2-yl)hept-5-enoic acid sodium salt] (an antagonist of prostanoid TP receptors) [100 and 250 microg (250 and 625 nmol)/animal)], and abolished by acute bilateral adrenalectomy. On the other hand, the prostaglandin E2-induced elevation of plasma noradrenaline was not influenced by acute bilateral adrenalectomy. These results suggest that adrenal noradrenaline secretion and sympathetic noradrenaline release are mediated by differential central mechanisms; brain prostanoid TP receptors activated by bombesin are involved in the adrenal noradrenaline secretion, while brain prostanoid EP (probably EP3) receptors activated by prostaglandin E2 are involved in the sympathetic noradrenaline release in rats. Brain prostanoid TP receptors activated by bombesin are also involved in the adrenal adrenaline secretion.
Collapse
Affiliation(s)
- Keiko Yokotani
- Department of Neuropharmacology, Program of Neural Integration, Graduate School of Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Yalcin M, Savci V. Restoration of Blood Pressure by Centrally Injected U-46619, a Thromboxane A 2 Analog, in Hemorrhaged Hypotensive Rats: Investigation of Different Brain Areas. Pharmacology 2004; 70:177-87. [PMID: 15001818 DOI: 10.1159/000075546] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2003] [Accepted: 09/03/2003] [Indexed: 11/19/2022]
Abstract
In the present study, we investigated the cardiovascular effects of centrally injected U-46619, a thromboxane A(2) (TXA(2)) analog, and the central and peripheral mechanisms of these effects in hemorrhagic shock conditions. Hemorrhage was performed by withdrawing a total volume of 2.1 ml of blood/100 g body weight over a period of 10 min. Injections were made into the lateral cerebral ventricle (LCV), nucleus tractus solitarius (NTS), rostral ventrolateral medulla (RVLM) and paraventricular nucleus of hypothalamus (PVN). U-46619 (0.1, 1 and 2 microg) increased blood pressure and reversed hypotension in hemorrhagic shock. The pressor effect was dose- and time-dependent in all investigated brain areas. Heart rate changes were not significantly different in all groups. Pretreatment of rats with an injection of SQ-29548 (4 or 8 microg), a TXA(2) receptor antagonist, into the LCV, NTS, RVLM and PVN completely blocked the pressor effect of U-46619 (1 microg) injected into respective brain areas. Hemorrhage itself increased plasma adrenaline, noradrenaline, vasopressIN levels and renin activity. U-46619 (1 microg) injected into the LCV, PVN, RVLM and NTS produced additional increases in these hormone levels and in renin activity. Intravenous pretreatments of rats with prazosin (0.5 mg/kg), an alpha(1)-adrenoceptor antagonist, [beta-mercapto-beta,beta-cyclopentamethylenepropionyl(1), O-Me-Tyr(2),Arg(8)]- vasopressin (10 microg/kg), a vasopressin V(1)-receptor antagonist, or saralasin (250 microg/kg), an angiotensin II receptor antagonist, in hemorrhaged rats partially blocked the pressor response to U-46619 (1 microg) injected into the LCV, PVN, RVLM and NTS. Results show that centrally administered U-46619, a TXA(2) analog, increases blood pressure and reverses hypotension in hemorrhagic shock. Activation of central TXA(2) receptors mediates the pressor effect of the drug. Furthermore, the increases in plasma adrenaline, noradrenaline, vasopressin levels and renin activity are involved in these effects.
Collapse
Affiliation(s)
- Murat Yalcin
- Department of Physiology, Veterinary Faculty, Uludag University, Bursa, Turkey
| | | |
Collapse
|
20
|
Nakamura K, Okada S, Yamaguchi N, Shimizu T, Yokotani K, Yokotani K. Role of K+ Channels in M2 Muscarinic Receptor-Mediated Inhibition of Noradrenaline Release From the Rat Stomach. J Pharmacol Sci 2004; 96:286-92. [PMID: 15528842 DOI: 10.1254/jphs.fpj04036x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
Previously we reported the cholinergic M2 muscarinic receptor-mediated inhibition of noradrenaline release from the rat stomach (K. Yokotani, Y. Osumi. J Pharmacol Exp Ther. 1993;264:54-60). In the present study, we investigated the role of K+ channels in oxotremorine (a muscarinic receptor agonist)-induced inhibition of noradrenaline release using isolated, vascularly perfused rat stomach. The gastric postganglionic sympathetic nerves were electrically stimulated twice at 2.5 Hz for 1 min and test reagents were added during the second stimulation. The electrically evoked release of noradrenaline was augmented by tetraethylammonium and 4-aminopyridine (non-selective K+ channel blockers) and also by charybdotoxin (a blocker of big conductance Ca2+-activated K+ channel). On the other hand, apamin (a selective blocker of small conductance Ca2+-activated K+ channels) and glibenclamide (an ATP-activated K+ channel blocker) had no effect on the evoked noradrenaline release. Oxotremorine-induced inhibition of noradrenaline release was attenuated by tetraethylammonium and 4-aminopyridine, while the inhibition was not influenced by charybdotoxin, apamin, and glibenclamide. These results suggest that tetraethylammonium- and 4-aminopyridine-sensitive K+ channels (probably voltage-activated K+ channels) are involved in the muscarinic receptor-mediated inhibition of noradrenaline release from the rat stomach.
Collapse
Affiliation(s)
- Kumiko Nakamura
- Department of Neuropharmacology, Program of Neural Integration, Graduate School of Medicine, Kochi University, Nankoku, Japan
| | | | | | | | | | | |
Collapse
|
21
|
van Anholt RD, Spanings T, Koven W, Wendelaar Bonga SE. Effects of acetylsalicylic acid treatment on thyroid hormones, prolactins, and the stress response of tilapia (Oreochromis mossambicus). Am J Physiol Regul Integr Comp Physiol 2003; 285:R1098-106. [PMID: 12842867 DOI: 10.1152/ajpregu.00731.2002] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The cyclooxygenase (COX) pathway converts arachidonic acid (ArA) into prostaglandins (PGs), which interact with the stress response in mammals and possibly in fish as well. Acetylsalicylic acid (ASA) is a COX inhibitor and was used to characterize the effects of PGs on the release of several hormones and the stress response of tilapia (Oreochromis mossambicus). Plasma PGE2 was significantly reduced at 100 mg ASA/kg body wt, and both basal PGE2 and cortisol levels correlated negatively with plasma salicylate. Basal plasma 3,5,3'-triiodothyronine (T3) was reduced by ASA treatment, whereas prolactin (PRL)188 increased at 100 mg ASA/kg body wt. ASA depressed the cortisol response to the mild stress of 5 min of net confinement. As expected, glucose and lactate were elevated in the stressed control fish, but the responses were blunted by ASA treatment. Gill Na+-K+-ATPase activity was not affected by ASA. Plasma osmolarity increased after confinement in all treatments, whereas sodium only increased at the high ASA dose. This is the first time ASA has been administered to fish in vivo, and the altered hormone release and the inhibition of the acute stress response indicated the involvement of PGs in these processes.
Collapse
Affiliation(s)
- Rogier D van Anholt
- Dept. of Animal Ecology and Ecophysiology, Faculty of Science, Univ. of Nijmegen, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands.
| | | | | | | |
Collapse
|
22
|
Okada S, Yokotani K, Yokotani K. Inducible nitric oxide synthase is involved in corticotropin-releasing hormone-mediated central sympatho-adrenal outflow in rats. Eur J Pharmacol 2003; 477:95-100. [PMID: 14519412 DOI: 10.1016/j.ejphar.2003.08.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Brain nitric oxide (NO), recognized as a neurotransmitter or a neuromodulator, is mainly generated either by neuronal NO synthase (NOS) or by inducible NOS. NO has been shown to activate cyclooxygenase (a prostaglandin-forming enzyme) in addition to guanylate cyclase. Recently, we reported that the intracerebroventricularly (i.c.v.) administered corticotropin-releasing hormone (CRH) increases plasma catecholamines through brain cyclooxygenase-dependent mechanisms in rats. In the present experiments, therefore, we examined whether NO is involved in the CRH-induced increase of plasma catecholamines using urethane-anesthetized rats. I.c.v. administered CRH increased plasma noradrenaline and adrenaline in a dose-dependent manner (0.5, 1.5, and 3.0 nmol/animal). The CRH (1.5 nmol/animal, i.c.v.)-induced increase of plasma catecholamines was reduced by N(omega)-nitro-L-arginine methyl ester (a non-selective inhibitor of NOS) [111 nmol (30 microg)/animal, i.c.v.], but not by the same dose of N(omega)-nitro-D-arginine methyl ester (an inactive isomer of N(omega)-nitro-L-arginine methyl ester). The CRH-induced increase of plasma catecholamines was also reduced either by cycloheximide (an inhibitor of protein synthesis) [107 nmol (30 microg)/animal, i.c.v.] or by S-methylisothiourea (an inhibitor of inducible NOS) [71 nmol (20 microg) and 711 nmol (200 microg)/animal, i.c.v.]. These results suggest the involvement of brain inducible NOS in the CRH-induced activation of the central sympatho-adrenomedullary outflow in rats.
Collapse
Affiliation(s)
- Shoshiro Okada
- Department of Pharmacology, Kochi Medical School, Nankoku, 783-8505 Kochi, Japan
| | | | | |
Collapse
|
23
|
Okada S, Shimizu T, Yokotani K. Brain phospholipase C and diacylglycerol lipase are involved in corticotropin-releasing hormone-induced sympatho-adrenomedullary outflow in rats. Eur J Pharmacol 2003; 475:49-54. [PMID: 12954358 DOI: 10.1016/s0014-2999(03)02148-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Previously, we reported that the elevation of plasma noradrenaline and adrenaline induced by intracerebroventricularly (i.c.v.) administered corticotropin-releasing hormone (CRH) was abolished by i.c.v. administered indomethacin, an inhibitor of cyclooxygenase, in rats [Yokotani et al., Eur. J. Pharmacol. 419, 183-189, 2001]. The result suggests the involvement of active metabolites of brain arachidonic acid in the CRH-induced activation of the central sympatho-adrenomedullary outflow. Arachidonic acid is released mainly by two different pathways: phospholipase A2-dependent pathway; phospholipase C- and diacylglycerol lipase-dependent pathway. In the present study, therefore, we tried to identify which pathway is involved in the CRH-induced elevation of plasma catecholamines in urethane-anesthetized rats. CRH (1.5 nmol/animal, i.c.v.)-induced elevation of plasma noradrenaline and adrenaline was abolished by neomycin [0.55 micromol (500 microg)/animal, i.c.v.] and 1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U-73122) [5 nmol (2.3 microg)/animal, i.c.v.] (inhibitors of phospholipase C), and also by 1,6-bis-(cyclohexyloximinocarbonylamino)-hexane (RHC-80267) [1.3 micromol (500 microg)/animal, i.c.v.] (an inhibitor of diacylglycerol lipase). On the other hand, mepacrine [1.1 micromol (500 microg)/animal, i.c.v.] (an inhibitor of phospholipase A2) and 1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-2,5-pyrrolidinedione (U-73343) [5 nmol (2.3 microg)/animal, i.c.v.] (an inactive analog of U-73122) had no effect. These results suggest that CRH activates the central sympatho-adrenomedullary outflow by the brain phospholipase C- and diacylglycerol lipase-dependent mechanisms in rats.
Collapse
Affiliation(s)
- Shoshiro Okada
- Department of Neuropharmacology, Program of Neural Integration, Kochi Medical School, Nankoku, Kochi 783-8505, Japan
| | | | | |
Collapse
|
24
|
Okada S, Shimizu T, Yokotani K. Extrahypothalamic corticotropin-releasing hormone mediates (-)-nicotine-induced elevation of plasma corticosterone in rats. Eur J Pharmacol 2003; 473:217-23. [PMID: 12892841 DOI: 10.1016/s0014-2999(03)01966-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
(-)-Nicotine activates the hypothalamic-pituitary-adrenal axis via an activation of the brainstem catecholaminergic neurons in rats. The present study was undertaken to clarify the mechanisms involved in the (-)-nicotine-induced activation of brainstem catecholaminergic neurons in anesthetized rats. Physostigmine (a cholinesterase inhibitor) (0.31 and 0.77 micromol/animal, i.p.) dose-dependently elevated plasma corticosterone in the presence of scopolamine (a muscarinic receptor antagonist) (2.3 micromol/animal, i.p.). (-)-Nicotine (250 and 500 nmol/animal, i.c.v.) dose-dependently elevated plasma corticosterone with concomitant noradrenaline release in the hypothalamic paraventricular nucleus. The (-)-nicotine (500 nmol/animal, i.c.v.)-induced elevation of corticosterone was abolished by phentolamine (an alpha-adrenoceptor antagonist) (0.66 micromol/animal, i.c.v.), and attenuated by (+/-)-sotalol (a beta-adrenoceptor antagonist) (0.97 micromol/animal, i.c.v.). The (-)-nicotine-induced increases of plasma corticosterone and hypothalamic noradrenaline release were abolished either by hexamethonium (a nicotinic acetylcholine receptor antagonist) (1.8 micromol/animal, i.c.v.), CP-154,526 (butyl-ethyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine) (a selective CRF-1 receptor antagonist) (1.3 micromol/animal, i.c.v.) or indomethacin (a cyclooxygenase inhibitor) (1.2 micromol/animal, i.c.v.). These results suggest that (-)-nicotine elevates plasma corticosterone by CRF-1 receptor- and prostaglandin-mediated noradrenaline release in the paraventricular nucleus in rats.
Collapse
Affiliation(s)
- Shoshiro Okada
- Department of Pharmacology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan
| | | | | |
Collapse
|
25
|
Nakamura K, Okada S, Ono K, Yokotani K. Effects of 8-iso-prostaglandin E2 and 8-iso-prostaglandin F2 alpha on the release of noradrenaline from the isolated rat stomach. Eur J Pharmacol 2003; 470:73-8. [PMID: 12787833 DOI: 10.1016/s0014-2999(03)01756-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In the present experiment, we examined the effect of 8-iso-prostaglandin E(2) and 8-iso-prostaglandin F(2 alpha) on the release of noradrenaline from the isolated rat stomach. The postganglionic sympathetic nerves were electrically stimulated twice at 1 Hz for 1 min and test reagents were added during the second stimulation. 8-Iso-prostaglandin E(2) (10(-8)-10(-6) M) and 8-iso-prostaglandin F(2 alpha) (10(-7)-10(-5) M) dose-dependently reduced the evoked noradrenaline release, and these inhibitory potencies were as follows: 8-iso-prostaglandin E(2)>8-iso-prostaglandin F(2 alpha). The inhibitory effect of 8-iso-prostaglandin F(2 alpha), but not 8-iso-prostaglandin E(2), was abolished by 10(-6) M SQ-29548 ([1S-[1 alpha,2 alpha(Z),3 alpha,4 alpha]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino] methyl]-7-oxabicyclo[2,2,1]hept-2-yl]-5-heptenoic acid) (a prostanoid TP receptor antagonist). On the other hand, the inhibitory effect of 8-iso-prostaglandin E(2) was abolished by 10(-5) M AH-6809 (6-isopropoxy-9-oxoxanthene-2-carboxylic acid) (a prostanoid EP receptor antagonist), which also attenuated the inhibitory effects of ONO-AE-248 (16S-9-deoxy-9 beta-chloro-15-deoxy-16-hydroxy-17,17-trimethylene 19, 20-didehydro prostaglandin F(2)) (a selective EP(3) receptor agonist) on the evoked release of noradrenaline. The inhibitory effect of 8-iso-prostaglandin F(2 alpha), but not 8-iso-prostaglandin E(2), was abolished by pertussis toxin. These results suggest that 8-iso-prostaglandin F(2 alpha) inhibits noradrenaline release through TP receptors, whereas 8-iso-prostaglandin E(2) seems to inhibit noradrenaline release through EP(3) receptors, located on the gastric sympathetic nerve terminals in rats.
Collapse
Affiliation(s)
- Kumiko Nakamura
- Department of Pharmacology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan
| | | | | | | |
Collapse
|
26
|
Husted D, Upshaw J, Gridley KE, Wood CE. Cellular localization of thromboxane synthase in ovine spinal cord and hindbrain. Brain Res 2003; 971:107-15. [PMID: 12691843 DOI: 10.1016/s0006-8993(03)02400-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
We and others have demonstrated that endogenously-produced prostanoids modify the function of the hypothalamus-pituitary-adrenal (HPA) axis. We have demonstrated that exogenously-administered thromboxane mimetic stimulates ACTH secretion in fetal sheep, and that the endogenous production of thromboxane modifies the HPA response to cardiovascular stress. The purpose of this study was to identify the structures within the fetal and adult ovine medulla and hindbrain which express immunoreactive thromboxane synthase. Using immunohistochemical techniques, we demonstrated thromboxane synthase immunostaining in regions important for cardiovascular afferent signaling (nucleus tractus solitarius, ventrolateral medulla) in both cell bodies and axons. Thromboxane synthase was also apparent in neuroanatomical locations which are consistent with afferent and efferent projections from the cerebellum. We observed staining in the superior cerebellar peduncle in the rostal pons, in the corticopontocerebellar fibers, and in Purkinje cells. The enzyme was found in motor regions, including the dorsal motor nucleus of the vagus nerve, and in the motor neurons of the dorsal column of the spinal cord. In addition to the apparent neuronal staining, there was positive staining in the ventricular ependymal cells. We conclude that, consistent with physiological evidence, thromboxane synthase is present in brain regions which are important for afferent and efferent cardiovascular signaling.
Collapse
Affiliation(s)
- David Husted
- Department of Physiology and Functional Genomics, PO Box 100274, University of Florida College of Medicine, Gainesville, FL 32610-0274, USA
| | | | | | | |
Collapse
|
27
|
Okada S, Murakami Y, Yokotani K. Role of brain thromboxane A2 in the release of noradrenaline and adrenaline from adrenal medulla in rats. Eur J Pharmacol 2003; 467:125-31. [PMID: 12706465 DOI: 10.1016/s0014-2999(03)01629-7] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Plasma noradrenaline reflects the release from adrenal medulla and sympathetic nerves; however, the exact mechanisms of adrenal noradrenaline release remain to be elucidated. The present study was designed to characterize the source of plasma noradrenaline induced by centrally administered vasopressin and corticotropin-releasing hormone (CRH) in urethane-anesthetized rats. Intracerebroventricularly administered vasopressin (0.2 nmol/animal) and CRH (1.5 nmol/animal) elevated plasma levels of noradrenaline and adrenaline. Intracerebroventricularly administered indomethacin [1.2 micromol (500 microg)/animal] (an inhibitor of cyclooxygenase) abolished the elevations of both noradrenaline and adrenaline induced by vasopressin and CRH. Intracerebroventricularly administered furegrelate [1.8 micromol (500 microg)/animal] (an inhibitor of thromboxane A(2) synthase) abolished the elevations of both noradrenaline and adrenaline induced by vasopressin, while the reagent only attenuated the elevation of plasma adrenaline evoked by CRH. Acute bilateral adrenalectomy abolished the elevation of both noradrenaline and adrenaline induced by vasopressin, while the procedure reduced only the elevation of adrenaline induced by CRH. These results suggest that the release of noradrenaline from adrenal medulla and sympathetic nerves is mediated by different central mechanisms. The vasopressin-induced noradrenaline release from adrenal medulla is mediated by brain thromboxane A(2)-mediated mechanisms, while the CRH-induced noradrenaline release from sympathetic nerves is mediated by brain prostanoid (other than thromboxane A(2))-mediated mechanisms. The vasopressin- and CRH-induced adrenaline release from adrenal medulla is also mediated by brain thromboxane A(2)-mediated mechanisms in rats.
Collapse
Affiliation(s)
- Shoshiro Okada
- Department of Pharmacology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan
| | | | | |
Collapse
|
28
|
Yokotani K, Nakamura K, Okada S. Prostanoid EP3 and TP receptors-mediated inhibition of noradrenaline release from the isolated rat stomach. Eur J Pharmacol 2003; 459:187-93. [PMID: 12524145 DOI: 10.1016/s0014-2999(02)02857-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The postganglionic sympathetic nerves of the isolated rat stomach were electrically stimulated twice at 1 Hz for 1 min. Prostaglandin E(2) and ONO-AE-248 (16S-9-deoxy-9beta-chloro-15-deoxy-16-hyfroxy-17,17-trimethylene-19,20-didehydro prostaglandin F(2)) (an EP(3) receptor agonist) reduced the evoked noradrenaline release, while ONO-DI-004 (17S-2,5-ethano-6-oxo-17,20-dimethyl prostaglandin E(1)) (an EP(1) receptor agonist), ONO-AE1-259-01 (11,15-O-dimethyl prostaglandin E(2)) (an EP(2) receptor agonist) and ONO-AE1-329 [16-(3-methoxymethyl)phenyl-omega-tetranor-3,7-dithia prostaglandin E(1)] (an EP(4) receptor agonist) had no effect. U-46619 (9,11-dideoxy-9alpha,11alpha-methanoepoxy prostaglandin F(2alpha)) and I-BOP (7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo[2,2,1] hept-2-yl]-,[1S[1alpha,2alpha(Z),3beta(1E,3S)4alpha]]-5-heptenoic acid) (TP receptor agonists) also reduced the noradrenaline release and these inhibitory effects were abolished by SQ-29548 (7-[3-[[2-[(phenylamino) carbonyl] hydrazino]methyl]-7-oxabicyclo[2,2,1]hept-2-yl][1S(1alpha,2alpha(Z), 3alpha,4alpha]-5-heptenoic acid) (a TP receptor antagonist). The inhibitory effect of U-46619, but not ONO-AE-248, was abolished by pertussis toxin. These results suggest that the prostanoid EP(3) and TP receptors mediate the inhibition of gastric noradrenaline release; TP, but not EP(3), receptor-mediated inhibition is mediated by a pertussis toxin-sensitive mechanism in rats.
Collapse
Affiliation(s)
- Kunihiko Yokotani
- Department of Pharmacology, Kochi Medical School, Nankoku, 783-8505, Kochi, Japan.
| | | | | |
Collapse
|
29
|
Nakamura K, Okada S, Yokotani K. Endothelin ET A- and ET B-receptor-mediated inhibition of noradrenaline release from isolated rat stomach. J Pharmacol Sci 2003; 91:34-40. [PMID: 12686728 DOI: 10.1254/jphs.91.34] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
We examined the effect of endothelin-1, endothelin-3 and sarafotoxin S6c on the release of noradrenaline from gastric sympathetic nerve terminals using an isolated, vascularly perfused rat stomach. The release of noradrenaline evoked by electrical stimulation of the gastric postganglionic sympathetic nerves (at 2.5 Hz for 1 min) was inhibited by endothelin-1 (10(-)(10) - 10(-)(8) M), endothelin-3 (10(-)(9) - 10(-)(8) M) and sarafotoxin S6c (a highly selective agonist of endothelin ET(B) receptors) (10(-)(9) - 10(-)(8) M) in a concentration-dependent manner; the inhibitory potencies were as follows: endothelin-1 > endothelin-3 > sarafotoxin S6c. The inhibitory effect of endothelin-1 (3 x 10(-)(9) M) on noradrenaline release was abolished by BQ-123 (a selective antagonist of endothelin ET(A) receptors) in a dose-dependent manner (10(-)(7) and 10(-)(6) M), but not influenced by BQ-788 (a selective antagonist of endothelin ET(B) receptors) (10(-)(7) and 10(-)(6) M). The endothelin-1-induced inhibition of noradrenaline release was attenuated by pretreatment with pertussis toxin (10 micro g/animal, i.v., 4 days before experiments), but not influenced by indomethacin (3 x 10(-)(6) M). These results indicate that endothelin ET(A) and ET(B) receptors located on the sympathetic nerve terminals play a role in the inhibition of noradrenaline release from the rat stomach: endothelin ET(A) receptor-mediated inhibition is carried out by pertussis toxin-sensitive and indomethacin-insensitive mechanisms.
Collapse
|
30
|
Okada S, Murakami Y, Nakamura K, Yokotani K. Vasopressin V(1) receptor-mediated activation of central sympatho-adrenomedullary outflow in rats. Eur J Pharmacol 2002; 457:29-35. [PMID: 12460640 DOI: 10.1016/s0014-2999(02)02652-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The present study was designed to characterize the vasopressin receptor subtype involved in the vasopressin-induced activation of the central sympatho-adrenomedullary outflow using urethane-anesthetized rats. Intracerebroventricularly (i.c.v.) administered vasopressin (0.1, 0.2 and 0.5 nmol/animal) dose-dependently elevated plasma levels of adrenaline and noradrenaline (adrenaline>noradrenaline). The vasopressin (0.2 nmol/animal)-induced elevation of both catecholamines was significantly attenuated by [d(CH(2))(5)(1),Tyr(Me)(2),Arg(8)]-vasopressin, a selective vasopressin V(1) receptor antagonist, in a dose-dependent manner (0.1 and 0.2 nmol/animal, i.c.v.). The same doses (0.1 and 0.2 nmol/animal, i.c.v.) of [1-adamantaneacetyl(1),D-Tyr(Et)(2),Val(4),Abu(6), Arg(8,9)]-vasopressin, a potent vasopressin V(2) receptor antagonist, had no effect; however, a large dose of this antagonist (1.6 nmol/animal, i.c.v.) effectively reduced the vasopressin-induced elevation of catecholamines. On the other hand, [5-dimethylamino-1-[4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine], a selective vasopressin V(2) receptor antagonist (5 and 10 nmol/animal, i.c.v.), had no effect on the vasopressin-induced elevation of catecholamines. The vasopressin-induced elevation of catecholamines was abolished by indomethacin, an inhibitor of cyclooxygenase (1.2 micromol/animal, i.c.v.). These results suggest that the vasopressin activates the central sympatho-adrenomedullary outflow by brain vasopressin V(1) receptor- and cyclooxygenase-dependent mechanisms in rats.
Collapse
Affiliation(s)
- Shoshiro Okada
- Department of Pharmacology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan
| | | | | | | |
Collapse
|
31
|
Murakami Y, Okada S, Yokotani K. Brain inducible nitric oxide synthase is involved in interleukin-1beta-induced activation of the central sympathetic outflow in rats. Eur J Pharmacol 2002; 455:73-8. [PMID: 12433597 DOI: 10.1016/s0014-2999(02)02580-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Nitric oxide (NO) has been recognized as a neurotransmitter or a neuromodulator in the central nervous system. Brain NO is mainly generated either by neuronal NO synthase (NOS) or by inducible NOS. Previously we reported that central NO is involved in the elevation of plasma noradrenaline levels induced by intracerebroventricularly (i.c.v.) administered interleukin-1beta in rats [Eur. J. Phamacol. 317 (1996) 61]. In the present study, therefore, we tried to characterize which type of NOS isoforms is involved in the cytokine-induced responses using selective inhibitors of each NOS isoform in urethane-anesthetized rats. I.c.v. administered interleukin-1beta (100 ng/animal) elevated plasma levels of noradrenaline but not adrenaline. The cytokine-induced elevation of plasma noradrenaline levels was attenuated by cycloheximide, an inhibitor of protein synthesis, in a dose-dependent manner (10 and 20 microg/animal, i.c.v.). S-ethylisothiourea (0.1 and 0.5 microg/animal, i.c.v.), an inhibitor of inducible NOS, dose-dependently reduced the cytokine-induced elevation of plasma noradrenaline levels, while 7-nitroindazole (5 and 10 microg/animal, i.c.v.), an inhibitor of neuronal NOS, had no effect. These results suggest the involvement of brain inducible NOS in the interleukin-1beta-induced activation of the central sympathetic outflow in rats.
Collapse
Affiliation(s)
- Yoshinori Murakami
- Department of Pharmacology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan
| | | | | |
Collapse
|
32
|
Murakami Y, Okada S, Nishihara M, Yokotani K. Roles of brain prostaglandin E2 and thromboxane A2 in the activation of the central sympatho-adrenomedullary outflow in rats. Eur J Pharmacol 2002; 452:289-94. [PMID: 12359269 DOI: 10.1016/s0014-2999(02)02308-7] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We examined the effects of centrally administered active metabolites of the arachidonic acid cascade on activation of the central sympatho-adrenomedullary outflow using urethane-anaesthetized rats. Intracerebroventricularly (i.c.v.) administered prostaglandin E(2) (0.3 nmol/animal) significantly elevated plasma levels of noradrenaline while levels of adrenaline were not affected. Prostaglandin D(2), prostaglandin F(2 alpha) and prostaglandin I(2) at the same dose (0.3 nmol/animal, i.c.v.) had no effect on plasma levels of either catecholamine. Thromboxane A(2) mimetic, 7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo [2.2.1]hept-2-yl], [1S-[1 alpha,2 alpha(Z),3beta(1E,3S),4 alpha]]-5-heptenoic acid (I-BOP) (5 and 10 pmol/animal) microinjected into the paraventricular nucleus of the hypothalamus significantly elevated plasma levels of adrenaline, but had little effect on plasma levels of noradrenaline. The I-BOP-induced (10 pmol/animal) elevation of plasma adrenaline levels was abolished by (+)-(1R,2R,3S,4S)-(5Z)-7-(3-[4-3H]-phenylsulphonyl-aminobicyclo[2.2.1]hept-2-yl)hept-5-enoic acid sodium salt [(+)-S-145] (a blocker of thromboxane A(2) receptors) [625 nmol (250 micro g)/animal, i.c.v.]. These results suggest that brain prostaglandin E(2) and thromboxane A(2) are respectively involved in the activation of the central sympathetic and adrenomedullary outflow in rats.
Collapse
Affiliation(s)
- Yoshinori Murakami
- Department of Pharmacology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan
| | | | | | | |
Collapse
|
33
|
Okada S, Murakami Y, Yokotani K. Centrally applied nitric oxide donor elevates plasma corticosterone by activation of the hypothalamic noradrenergic neurons in rats. Brain Res 2002; 939:26-33. [PMID: 12020848 DOI: 10.1016/s0006-8993(02)02540-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The present study was undertaken to investigate the mechanisms involved in a nitric oxide donor [3-morpholino-sydnonimine (SIN-1)]-induced activation of hypothalamic-pituitary-adrenal axis in urethane- and alpha-chloralose-anesthetized rats. Intracerebroventricularly (i.c.v.) administered SIN-1 (250 and 500 microg/animal) effectively and dose-dependently elevated plasma levels of corticosterone. Pretreatment with phentolamine (250 microg/animal, i.c.v.), an alpha-adrenoceptor antagonist, attenuated the elevation of plasma corticosterone evoked by SIN-1, but sotalol (300 microg/animal, i.c.v.), a beta-adrenoceptor antagonist, was without effects. The same doses of SIN-1 also increased the release of noradrenaline in the hypothalamic paraventricular nucleus (PVN) measuring microdialysis technique, and this increase was abolished by tetrodotoxin (1 microM) administered into the perfusion solution of the PVN. Furthermore, pretreatment with indomethacin (500 microg/animal, i.c.v.), a cyclooxygenase inhibitor, abolished the SIN-1-induced elevations of both noradrenaline in the PVN and plasma corticosterone. These results suggest that i.c.v. administered SIN-1 activates central noradrenergic neurons innervating the PVN by prostaglandin-mediated mechanisms. Released noradrenaline in the PVN elevates plasma levels of corticosterone via an activation of the central alpha-adrenoreceptors in rats.
Collapse
Affiliation(s)
- Shoshiro Okada
- Department of Pharmacology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan
| | | | | |
Collapse
|
34
|
Yokotani K, Murakami Y, Okada S, Hirata M. Role of brain arachidonic acid cascade on central CRF1 receptor-mediated activation of sympatho-adrenomedullary outflow in rats. Eur J Pharmacol 2001; 419:183-9. [PMID: 11426840 DOI: 10.1016/s0014-2999(01)00987-6] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The present experiments were designed to characterize the mechanisms involved in the corticotropin releasing factor (CRF)-induced activation of central sympatho-adrenomedullary outflow in rats. Intracerebroventricularly (i.c.v.) administered CRF and urocortin (0.5, 1.5 and 3.0 nmol/animal) effectively and dose-dependently elevated plasma levels of adrenaline and noradrenaline, and the effect of urocortin was almost the same as that of CRF. The elevation of catecholamines induced by CRF and urocortin (1.5 nmol/animal) was reduced by CP-154,526(butyl-ethyl-(2,5-dimethyl-7-(2,4,6trimethylphenyl)-7H-pyrrolo [2,3-d] pyrimidin-4-yl]amine), a selective CRF1 receptor antagonist, in a dose dependent manner (1.2 and/or 2.4 micromol/animal, i.c.v.), and abolished by indomethacin (1.2 micromol/animal, i.c.v.), an inhibitor of cyclooxygenase. Furegrelate (1.8 micromol/animal, i.c.v.), an inhibitor of thromboxane A2 synthase, abolished the CRF-induced elevation of adrenaline, but had no effect on the evoked release of noradrenaline. These results suggest that activation of brain CRF1 receptor facilitates the central sympathetic and adrenomedullary outflow in distinct central pathways in rats; brain thromboxane A2 is involved in the central adrenomedullary outflow; an active metabolite of arachidonic acid other than thromboxane A2 (probably prostaglandin E2) may be involved in the central sympathetic outflow.
Collapse
Affiliation(s)
- K Yokotani
- Department of Pharmacology, Kochi Medical School, Japan.
| | | | | | | |
Collapse
|